Tyrosine kinase inhibitor drugs.

PreclinicalSmall molecule

Tyrosine kinase inhibitor drugs. is one of 6 small molecule programs targeting Thyroid Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CarcinomaActive, not recruiting

Thyroid CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Thyroid Carcinoma

#DrugCompanyPhaseTrials

Lenvima

Eisai

Approved

—2

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 3

Lanoxin

AAdvanz Pharma

Preclinical

1 4

Tirosint

IInstitut Jerome Lejeune

Iodine-124

1 6

Tyrosine kinase inhibitor drugs.

FFujian Cancer Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid Carcinoma1 trial

HRQOL in Locally Advanced Thyroid Carcinoma

Unknown status·FFujian Cancer Hospital··NCT05824312·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tyrosine kinase inhibitor drugs.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tyrosine kinase inhibitor drugs. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tyrosine kinase inhibitor drugs.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFujian Cancer Hospital

Tyrosine kinase inhibitor drugs.

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid Carcinoma1 trial

References

Drug Info

Quick Facts

Related News